-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

Benzinga·08/13/2026 14:16:00
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.